Evaluation of Serum Urate Levels and the Clinical Manifestation of Gout with Cardiovascular Mortality from the CARES Trial

Arthritis Rheum

In CARES, febuxostat and allopurinol (≤600 mg doses) had comparable efficacy in patients with gout and cardiovascular disease, with no relationships between cardiovascular mortality and sUA, gout flares, or tophus resolution with febuxostat.